The DOI matches its Crossref record.
Corticosteroids for pulmonary sarcoidosis
Open accessAbstract
BACKGROUND: Pulmonary sarcoidosis is a common condition with an unpredictable course. Oral (OCS) or inhaled steroids (ICS) are widely used in its treatment, but there is no consensus about when and in whom therapy should be initiated, what dose should be given and for how long. Corticosteroids given for several months have deleterious side-effects so it is important to know whether they have any maintained benefit in pulmonary sarcoidosis. OBJECTIVES: To determine the randomised controlled trial (RCT) evidence for the benefit of corticosteroids (oral or inhaled) in the treatment of pulmonary sarcoidosis. SEARCH STRATEGY: MEDLINE, EMBASE and CENTRAL were searched using predefined terms. Bibliographies of retrieved RCTs and reviews were searched for additional RCTs. Pharmaceutical companies and authors of identified RCTs were contacted for other published and unpublished studies. Searches are current as of May 2004. SELECTION CRITERIA: Two reviewers independently assessed full text articles for inclusion based upon the following criteria: the study had to be a RCT or controlled clinical trial in adults with histological evidence of pulmonary sarcoidosis, treated with OCS (oral steroids) or ICS (oral steroids), compared with a control. DATA COLLECTION AND ANALYSIS: Study quality was assessed and data extracted independently by two reviewers. The primary outcome was CXR (chest x-ray). Outcomes were analysed as continuous and dichotomous outcomes, using standard statistical techniques. Heterogeneity was explored where it was identified. MAIN RESULTS: Twelve RCTs of variable quality involving 1051 participants met the inclusion criteria of the review. The oral steroid dose was equivalent to prednisolone 4-40 mg/day. OCS: there was an improvement in CXR over 3-24 months (Relative Risk (RR): 1.46 [1.01 to 2.09], 3 studies), but this finding requires cautious interpretation. No other significant differences were identified on secondary outcomes. ICS: Data were inadequate to perform meaningful analysis of data on CXR. Two studies showed no improvement in lung function, In one study there was an improvement in diffusing capacity in the treated group. There were no data on side-effects. In one study symptoms improved at the end of six months of treatment. AUTHORS' CONCLUSIONS: Oral steroids improved the chest X-ray and a global score of CXR, symptoms and spirometry over 3-24 months. However, there is little evidence of an improvement in lung function. There are limited data beyond two years to indicate whether oral steroids have any modifying effect on long-term disease progression. Oral steroids may be of benefit for patients with Stage 2 and 3 disease with moderate to severe or progressive symptoms or CXR changes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Birnie, D. H., Sauer, W. H., Bogun, F., Cooper, J. M., Culver, D. A., Duvernoy, C. S., Judson, M. A., Kron, J., Mehta, D., Cosedis Nielsen, J., et al. (2014) · Heart Rhythm · doi:10.1016/j.hrthm.2014.03.043 · Cited by 1,479
Valeyre, D., Prasse, A., Nunes, H., Uzunhan, Y., Brillet, P.-Y., & Müller-Quernheim, J. (2014) · The Lancet · doi:10.1016/s0140-6736(13)60680-7 · Cited by 1,087
Spagnolo, P., Rossi, G., Trisolini, R., Sverzellati, N., Baughman, R. P., & Wells, A. U. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30064-x · Cited by 949
ERS clinical practice guidelines on treatment of sarcoidosis
Baughman, R. P., Valeyre, D., Korsten, P., Mathioudakis, A. G., Wuyts, W. A., Wells, A., Rottoli, P., Nunes, H., Lower, E. E., Judson, M. A., et al. (2021) · European Respiratory Journal · doi:10.1183/13993003.04079-2020 · Cited by 629
A Concise Review of Pulmonary Sarcoidosis
Baughman, R. P., Culver, D. A., & Judson, M. A. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201006-0865ci · Cited by 536
Metadata
- Authors
- Paramothayan, N. S., Lasserson, T. J., & Jones, P.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2005-04-20
- Volume
- 2010
- Issue
- 5
- Pages
- CD001114-CD001114
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W1863141532
- Cited by
- 198
- References
- 0
- FWCI
- 4.38
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Corticosteroids for pulmonary sarcoidosis. https://app.cochat.ai/papers/10.1002/14651858.cd001114.pub2
- The paper
- Paramothayan, N. S., Lasserson, T. J., & Jones, P. (2005). Corticosteroids for pulmonary sarcoidosis. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd001114.pub2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.